- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Association Between Bronchial Asthma and TSLP Gene Polymorphism: A Systematic Review and Meta-analysis (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5615;
This meta-analysis shows that the SNP rs2289278 has a protective effect on the development of asthma; whereas rs3806933 has a risk of asthma. Additionally, this study adds genomic-based support to the recent FDA approval of tezepelumab, an anti-TSLP agent.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen, Fasenra (benralizumab) / AstraZeneca
Biologics for Severe Asthma in Patients With Asthma-Chronic Obstructive Pulmonary Disease Overlap (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5607;
These results suggest that biologics are effective for severe asthma in ACO patients. Therefore, physicians should carefully evaluate the severity of asthma in ACO patients and provide treatment with biologics if necessary.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Nocardia as a Cause of Non-Resolving Pneumonia and Uncontrolled Asthma in a Patient on Biologics (San Diego Convention Center, Area H (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_4096;
This was seen in our case of a 49-year-old male with uncontrolled asthma treated with a monthly injection of Dupixent initially and then switched to Tezepelumab-ekko (TEK)...TMP-SMX caused an allergic reaction in the patient and the antibiotics management had to change awaiting sensitivities...Our case highlights the importance of considering immunomodulatory medications as a cause of opportunistic infections when formulating a differential diagnosis. We encourage reporting of similar cases to help in identifying associations with immunomodulatory medications and opportunistic infections since the use of biologics for asthma control is becoming a new approach to treatment.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: Tezepelumab and Mucus Plugs in Patients with Moderate-to-Severe Asthma. (Pubmed Central) - Feb 10, 2024
At baseline, mucus plug scores correlated positively with levels of inflammatory biomarkers and negatively with lung function measures. Patients treated with tezepelumab had resolution of more mucus plugs than patients taking placebo.
- |||||||||| Review, Journal: The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs. (Pubmed Central) - Feb 10, 2024
Despite the undeniable economic impact of biologic therapies, in the near future, there will be room for further reflection about the opportunity to prescribe biologic agents, not only as a last-line therapy in selected cases such as patients with comorbidities involving common pathways. Although recent findings are very encouraging, the road to permanent success in the treatment of EoE is still long, and further studies are needed to determine the long-term effects of mAbs and to discover new potential targets.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Enrollment open: Tezepelumab in Allergic Rhinitis and Asthma Study (TEZARS) (clinicaltrials.gov) - Feb 6, 2024
P2, N=19, Recruiting,
Although recent findings are very encouraging, the road to permanent success in the treatment of EoE is still long, and further studies are needed to determine the long-term effects of mAbs and to discover new potential targets. Not yet recruiting --> Recruiting
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: Tezepelumab (Tezspire (Pubmed Central) - Jan 19, 2024
Tezepelumab proved a broad anti-inflammatory effect by blocking IL-4, IL-13 and IL-5 pathways, inducing a significant reduction in serum total IgE levels, FeNO, blood and sub-mucosal eosinophils, without affecting neutrophil level. Tezepelumab also reduced bronchial hyperresponsiveness and mucus plugs.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: Mechanism of action of tezepelumab (TEZSPIRE) and clinical trial results in ?asthma (Pubmed Central) - Jan 8, 2024
Clinical pharmacology trials demonstrated the efficacy of tezepelumab in improving airway hyperresponsiveness. In this article, we reviewed pharmacological characteristics, pharmacokinetics, clinical efficacy, and the safety profile of tezepelumab.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Trial completion date, Trial primary completion date: Tezepelumab on Airway Structure and Function in Patients With Uncontrolled Moderate-to-severe Asthma (clinicaltrials.gov) - Jan 4, 2024
P3, N=30, Recruiting,
In this article, we reviewed pharmacological characteristics, pharmacokinetics, clinical efficacy, and the safety profile of tezepelumab. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Review, Journal: Tezepelumab in patients with allergic and eosinophilic asthma. (Pubmed Central) - Dec 26, 2023
P2, P3
In a pooled analysis of the phase 2b PATHWAY (NCT02054130) and phase 3 NAVIGATOR (NCT03347279) studies, compared with placebo, tezepelumab reduced the annualized asthma exacerbation rate over 52?weeks by 62% (95% confidence interval [CI]: 53, 70) in patients with perennial aeroallergen sensitization (allergic asthma); by 71% (95% CI: 62, 78) in patients with a baseline blood eosinophil count ?300 cells/?L; and by 71% (95% CI: 59, 79) in patients with allergic asthma and a baseline blood eosinophil count ?300 cells/?L. This review examines the efficacy and mode of action of tezepelumab in patients with allergic asthma, eosinophilic asthma and coexisting allergic and eosinophilic phenotypes.
- |||||||||| Review, Journal: An overview of new and emerging antibody therapies for moderate-severe atopic dermatitis in adults. (Pubmed Central) - Dec 6, 2023
Some monoclonal antibodies, such as dupilumab (anti-IL-4?R?) and tralokinumab (anti-IL13) are already approved for the treatment of moderate-to-severe atopic dermatitis, and numerous articles in the literature have demonstrated their efficacy and safety...Data from phase 2b and phase III clinical trials in moderate-to-severe atopic dermatitis in adults indicate that these drugs have a promising efficacy and safety profile. Monoclonal antibodies currently under investigation will be available in the coming years to enrich the therapeutic choice of new alternatives that are valid both in terms of efficacy and safety.
- |||||||||| Review, Journal: Unanswered questions on the use of biologics in pediatric asthma. (Pubmed Central) - Nov 29, 2023
Since the launch of omalizumab, several other biologics have been marketed or are close to being marketed, suggesting that a plethora of monoclonal antibodies can be expected in the coming years...For these reasons, along with the relatively short time of use with these treatments, there are recurrently arising questions for which there are not even moderately documented answers, and for which the only solution must be based, with all reservations, on the combination of indirect evidence and expertise. In this paper, we attempt to address such questions, providing relevant commentaries and considering the whole width of the evidence base.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Review, Journal: Tezepelumab: a new option for the treatment of severe asthma (Pubmed Central) - Nov 27, 2023
Therefore, in this review, we will show the clinical efficacy of tezepelumab in reducing the annual rate of exacerbations, improving lung function, and reducing bronchial hyperreactivity, regardless of the patient's baseline biomarker levels. Therefore, this new molecule is a highly effective therapeutic option for patients with severe asthma.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Trial initiation date, HEOR, Real-world evidence, Real-world: ASCENT: A Study for Observing Severe Asthma in Patients Treated With Tezepelumab (clinicaltrials.gov) - Oct 23, 2023
P=N/A, N=200, Recruiting,
Evaluating baseline biomarkers helps in choosing the proper biologics to maximize treatment effects. Initiation date: Dec 2022 --> Jun 2022
- |||||||||| Journal: Biotherapies in severe childhood asthma (Pubmed Central) - Oct 9, 2023
Such treatments mainly include biotherapies, and, in children, four monoclonal antibodies are presently available to treat severe asthma: omalizumab, mepolizumab, dupilumab and tezepelumab. These biotherapies have demonstrated short- and medium-term efficacy and safety in both adults and children.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Review, Journal: Positioning of Tezepelumab in severe asthma. (Pubmed Central) - Oct 9, 2023
Therefore, tezepelumab can be used in the whole spectrum of patients with severe uncontrolled asthma, especially in T2-high patients. This review includes a positioning statement by the authors, members of the SEAIC Asthma Committee.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Enrollment open: TezepelumabPRO: Tezepelumab PRO Study (clinicaltrials.gov) - Oct 3, 2023
P=N/A, N=90, Recruiting,
This review includes a positioning statement by the authors, members of the SEAIC Asthma Committee. Not yet recruiting --> Recruiting
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Review, Journal, Stroma: Tezepelumab: an anti-thymic stromal lymphopoietin monoclonal antibody for the treatment of asthma. (Pubmed Central) - Sep 19, 2023
In this narrative review, we describe the results of clinical trials that evaluated the pharmacokinetics, pharmacodynamics, efficacy and safety of tezepelumab in patients with moderate-to-severe asthma. We also introduce the ongoing clinical trials in patients with asthma as well as future trials investigating the use of tezepelumab for other indications.
- |||||||||| Review Of Biologic Efficacy In Patients With Uncontrolled Asthma By Age At Asthma Onset (Monitor 15) - Sep 14, 2023 - Abstract #ACAAI2023ACAAI_914;
Conclusion Among patients with moderate to severe, uncontrolled asthma, biologic efficacy by age at asthma onset aligned with biologic mechanisms of action and indications (allergic vs eosinophilic vs all phenotypes). These differences can help to identify patients more responsive to individual biologics, informing provider treatment decisions.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen, Fasenra (benralizumab) / AstraZeneca
Recent Real-World Biologic Utilization Among Adults With Severe Asthma: Data From The CHRONICLE Study (Monitor 14) - Sep 14, 2023 - Abstract #ACAAI2023ACAAI_905;
Conclusion Biologic initiations and switching frequency among patients with SA in the US have changed over time as new biologic therapies have been approved. In the most recent time interval, tezepelumab and dupilumab were the most commonly initiated biologics.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Timing Of Exacerbations With Tezepelumab Versus Placebo In Patients With And Without Symptomatic Perennial Allergy (Monitor 14) - Sep 14, 2023 - Abstract #ACAAI2023ACAAI_904;
P3
Reductions with tezepelumab compared with placebo were observed early in patients with and without confirmed symptomatic perennial allergy ( Figure ). Conclusion In patients with severe, uncontrolled asthma, tezepelumab treatment resulted in early and sustained reductions in the cumulative number of exacerbations compared with placebo, irrespective of confirmed symptomatic perennial allergy status.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Tezepelumab Reduces All Key Inflammatory Biomarker Levels In Patients With Severe Allergic And Eosinophilic Asthma (Monitor 14) - Sep 14, 2023 - Abstract #ACAAI2023ACAAI_901;
P2, P3
Patients who received tezepelumab also experienced greater improvements in ACQ-6 and AQLQ(S)+12 scores than those who received placebo (least-squares mean difference [95% confidence interval]: ?0.37 [?0.58, ?0.15] and 0.38 [0.15, 0.62], respectively). Conclusion Compared with placebo, tezepelumab reduced measured inflammatory biomarker levels and improved asthma control and health-related quality of life in patients with severe allergic and eosinophilic asthma.
- |||||||||| Review, Journal: Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps. (Pubmed Central) - Sep 9, 2023
With emerging evidence describing pathophysiology, novel targets for biologic monoclonal antibody treatments have been developed. There are currently six biologic therapies approved by the US Food and Drug Administration to treat asthma, including omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab, three of these-omalizumab, mepolizumab, and dupilumab-are also approved for NPs.
|
